8-KFiled Aug 5, 8:00 PM ET
Prime Medicine Reports Q2 2026 Financial Results
$PRME · Prime Medicine, Inc.Research Summary
AI-generated summary of this SEC filing
Prime Medicine Reports Q2 2026 Financial Results
What Happened
- On August 6, 2026, Prime Medicine, Inc. announced its financial results and business highlights for the quarter ended June 30, 2026 via a press release. The company furnished that press release as Exhibit 99.1 to the Form 8-K (Item 2.02).
Key Details
- Filing date: August 6, 2026 (Form 8-K).
- Quarter covered: quarter ended June 30, 2026 (Q2 2026).
- Exhibit: Press release dated August 6, 2026 is furnished as Exhibit 99.1.
- Report signed by CEO Allan Reine on behalf of the company.
Why It Matters
- This 8-K notifies investors that Prime Medicine has released its quarterly earnings and business updates; investors should review the furnished press release (and any accompanying XBRL data) to see reported earnings, revenue, guidance, or operational milestones.
- The filing itself does not include the numeric financials in the 8-K text—read the attached press release (Exhibit 99.1) for the specific figures and details that could affect investment decisions.